drugset / Trial / NCT01638325
A Study of Insulin Lispro With BioChaperone Excipient in Healthy Participants
RandomizedCrossoverSingle-blindBasic science
Summary
BC106 is a molecule that when injected with insulin lispro may change the speed of absorption of insulin lispro. The purpose of this study will be to evaluate the safety of BC106 insulin lispro and any side effects that might be associated with it, blood levels of insulin lispro after injection under the skin and how BC106 insulin lispro affects blood sugar after injection under the skin. There is a minimum 7 day washout between single doses.
Timeline
- Start
- 2012-07
- Primary completion
- 2012-09
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BC106 insulin lispro | Unknown | 15 iu | Subcutaneous |
| Subject | BC106 insulin lispro | Unknown | 30 iu | Subcutaneous |
| Comparator | Insulin Lispro | Protein / enzyme biologic | 15 iu | Subcutaneous |
Indications
No indication recorded.